drugset / Trial / NCT03053544
Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer
Phase 2
Completed
15 enrolled
Sunnybrook Health Sciences Centre
Sunnybrook Research Institute · collabUniversity of Toronto · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase II, single arm, controlled, open label internal pilot.
Timeline
- Start
- 2016-12-08
- Primary completion
- 2019-06-26
- Completion
- 2019-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | Oral |